Literature DB >> 8554943

Lack of effect of a 5-HT3 antagonist, pancopride, on lower oesophageal sphincter pressure in volunteers.

L Grande1, G Lacima, A Pérez, J M Zayas.   

Abstract

Effects of pancopride (5 and 10 mg, intravenously), on lower oesophageal sphincter pressure (LOESP), were assessed in healthy volunteers by means of oesophageal manometry. After pancopride 10 mg, the LOESP was higher than placebo and 5 mg pancopride but there were no differences among the three treatments (P = 0.42). The areas under the curve were similar without differences, neither with absolute measurements (P = 0.53) nor after a baseline correction (P = 0.16). In conclusion, pancopride has no clinically relevant effect on lower oesophageal sphincter pressure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8554943      PMCID: PMC1365160          DOI: 10.1111/j.1365-2125.1995.tb04563.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Effects of the 5-HT3 receptor antagonist, ICS 205-930, on oesophageal motor activity and on lower oesophageal sphincter pressure: a double-blind cross-over study.

Authors:  G Stacher; G Steiner; G Guapmann; G Stacher-Janotta; C Schneider; H Steinringer
Journal:  Hepatogastroenterology       Date:  1990-12

2.  Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs.

Authors:  G W Gullikson; R F Loeffler; M A Viriña
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

Review 3.  The 5-HT4 receptor: naughty, but nice.

Authors:  D E Clarke; D A Craig; J R Fozard
Journal:  Trends Pharmacol Sci       Date:  1989-10       Impact factor: 14.819

Review 4.  Pathogenesis of reflux esophagitis.

Authors:  W J Dodds; W J Hogan; J F Helm; J Dent
Journal:  Gastroenterology       Date:  1981-08       Impact factor: 22.682

5.  Dysphagia and esophageal motor dysfunction in gastroesophageal reflux are corrected by fundoplication.

Authors:  L Grande; G Lacima; E Ros; A Pujol; J C Garcia-Valdecasas; J Fuster; J Visa; C Pera
Journal:  J Clin Gastroenterol       Date:  1991-02       Impact factor: 3.062

Review 6.  Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications.

Authors:  N J Talley
Journal:  Aliment Pharmacol Ther       Date:  1992-06       Impact factor: 8.171

7.  The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons.

Authors:  A Dumuis; M Sebben; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

8.  Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa.

Authors:  G Stacher; H Bergmann; G V Granser-Vacariu; S Wiesnagrotzki; T A Wenzelabatzi; G Gaupmann; A Kugi; H Steinringer; C Schneider; J Höbart
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

9.  Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.

Authors:  A G Fernández; J Puig; J Beleta; T Doménech; J Bou; P Berga; R W Gristwood; D J Roberts
Journal:  Eur J Pharmacol       Date:  1992-11-10       Impact factor: 4.432

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.